leflunomide has been researched along with Myasthenia Gravis in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 5.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 5.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 5.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 1.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 1.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function." | 1.29 | Leflunomide prevents the development of experimentally induced myasthenia gravis. ( Apostolski, S; Bartlett, RR; Damjanovic, M; Isakovic, K; Kosec, D; Vidic-Dankovic, B, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X | 2 |
| Qiu, L | 3 |
| Lu, Y | 1 |
| Chen, J | 1 |
| Yang, W | 1 |
| Ou, C | 3 |
| Ran, H | 2 |
| Liu, W | 3 |
| Chen, P | 2 |
| Li, Y | 2 |
| Huang, H | 1 |
| Chen, Z | 1 |
| Liu, X | 1 |
| Huang, Z | 1 |
| Lin, Z | 1 |
| Feng, H | 1 |
| Deng, J | 1 |
| Luo, Y | 1 |
| Vidic-Dankovic, B | 1 |
| Kosec, D | 1 |
| Damjanovic, M | 1 |
| Apostolski, S | 1 |
| Isakovic, K | 1 |
| Bartlett, RR | 1 |
4 other studies available for leflunomide and Myasthenia Gravis
| Article | Year |
|---|---|
Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis.
Topics: Humans; Leflunomide; Myasthenia Gravis; Prednisone; Treatment Outcome | 2023 |
Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Cell Count; Child; Child, Preschool; Dendritic Cel | 2019 |
Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Topics: Activities of Daily Living; Adolescent; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; | 2016 |
Leflunomide prevents the development of experimentally induced myasthenia gravis.
Topics: Animals; Autoantibodies; Autoimmune Diseases; Female; Flow Cytometry; Immunization; Immunosuppressiv | 1995 |